Literature DB >> 2179420

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.

W T Hughes1, D Armstrong, G P Bodey, R Feld, G L Mandell, J D Meyers, P A Pizzo, S C Schimpff, J L Shenep, J C Wade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2179420     DOI： 10.1093/infdis/161.3.381

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  66 in total

Review 1.  Assessing ethics of trials in systematic reviews.

Authors:  Michael A Weingarten; Mical Paul; Leonard Leibovici
Journal:  BMJ       Date:  2004-04-24

2.  Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.

Authors:  J Feliu; A Artal; M González Barón; A Berrocal; I Chacón; M L García de Paredes; E Espinosa; A Ordóñez; P Zamora; J M Montero
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

3.  Multicentre Canadian clinical trials on neutropenic patients.

Authors:  R Feld
Journal:  Can J Infect Dis       Date:  1992-03

4.  Using filgrastim efficiently.

Authors:  G Dranitsaris
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

5.  Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Authors:  D Yamamura; R Gucalp; P Carlisle; M Cimino; J Roberts; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 6.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

7.  Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients.

Authors:  Aaron S Hess; Michael Kleinberg; John D Sorkin; Giora Netzer; Jennifer K Johnson; Michelle Shardell; Kerri A Thom; Anthony D Harris; Mary-Claire Roghmann
Journal:  Diagn Microbiol Infect Dis       Date:  2014-01-30       Impact factor: 2.803

Review 8.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 9.  Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.

Authors:  P Van der Auwera; J Gérain
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.